Terbogrel

Terbogrel
Names
IUPAC name
(5E)-6-{3-[tert-Butyl(cyano)carbamimidamido]phenyl}-6-pyridin-3-ylhex-5-enoic acid
Other names
(5E)-6-[m-(3-tert-Butyl-2-cyanoguanidino)phenyl]-6-(3-pyridyl)-5-hexenoic acid
Identifiers
149979-74-8 N
3D model (Jmol) Interactive image
ChEMBL ChEMBL281398 YesY
ChemSpider 4952549 YesY
KEGG D06077 YesY
PubChem 6449876
UNII 5Z4KWQ5OGN YesY
Properties
C23H27N5O2
Molar mass 405.49
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Terbogrel (INN)[1] blocks thromboxanes and is expected to be useful in treating the vasoconstricting and platelet-aggregating action of this compound. Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A synthase inhibitor.[2][3] The drug was developed by Boehringer Ingelheim.

See also

References

  1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 37" (PDF). WHO Drug Information. 11 (1): 49. 1997. Retrieved 3 December 2016.
  2. Guth, BD; Narjes, H; Schubert, HD; Tanswell, P; Riedel, A; Nehmiz, G (July 2004). "Pharmacokinetics and Pharmacodynamics of Terbogrel, a Combined Thromboxane A2 Receptor and Synthase Inhibitor, in Healthy Subjects". British Journal of Clinical Pharmacology. 58 (1): 40–51. doi:10.1111/j.1365-2125.2004.02083.x. PMC 1884538Freely accessible. PMID 15206991.
  3. Michaux, C; Norberg, B; Dogné, JM; Durant, F; Masereel, B; Delarge, J; Wouters, J (October 2000). "Terbogrel, a Dual-Acting Agent for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition". Acta Crystallographica. 56 (Pt 10): 1265–6. PMID 11025320.


This article is issued from Wikipedia - version of the 12/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.